EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fecal Microbiota Transplantation in Patients with Alcohol-Associated Cirrhosis: A Clinical Trial

Cristian Ichim iD, Adrian Boicean iD, Samuel Bogdan Todor, Paula Anderco, Victoria Bîrluțiu iD

Journal of Clinical Medicine · 24.08.2025 · 14 (17) · 5981

DOI: 10.3390/jcm14175981 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.08.2025. Verfasst von Cristian Ichim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550024 Sibiu, Romania. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gut microbiota dysregulation is increasingly recognized as a key contributor to the progression of liver cirrhosis and its complications, particularly hepatic encephalopathy. Fecal microbiota transplantation (FMT) has emerged as a novel therapeutic strategy aimed at restoring intestinal microbial homeostasis and modulating systemic inflammation.

Methods

This prospective, single-center clinical trial evaluated the short-term safety and efficacy of FMT in patients with alcohol-related liver cirrhosis. Clinical assessment, liver stiffness (via elastography), steatosis (controlled attenuation parameter), inflammatory biomarkers, and extended biochemical panels were analyzed at baseline, one week and one month post-FMT. A control group receiving standard medical therapy was used for comparison.

Results

FMT was associated with a significant reduction in hepatic encephalopathy severity (p = 0.014), sustained improvements in liver stiffness (p = 0.027) and decreased steatosis (p = 0.025). At one month, C-reactive protein and neutrophil-to-lymphocyte ratio both declined significantly (p = 0.043), indicating a measurable anti-inflammatory effect. No serious adverse events were recorded. In comparison with controls, FMT recipients showed lower systemic inflammation and improved neuropsychiatric status.

Conclusions

FMT demonstrated a favorable safety profile and yielded early clinical and biochemical benefits in patients with cirrhosis. These preliminary findings support the potential utility of microbiota-based interventions in chronic liver disease and warrant validation in larger, multicenter trials.

Schlagwörter

Stichwörter der Autor:innen

fecal microbiota transplantationgut–liver axishepatic encephalopathyliver cirrhosismicrobiota-based therapy

Autor:innen und Institutionen

  • Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550024 Sibiu, Romania.

ORCID-Profile: Cristian Ichim, Adrian Boicean, Victoria Bîrluțiu

Zitieren

APA

Ichim, C., Boicean, A., Todor, S. B., Anderco, P., & Bîrluțiu, V. (2025). Fecal Microbiota Transplantation in Patients with Alcohol-Associated Cirrhosis: A Clinical Trial. Journal of Clinical Medicine, 14(17), 5981. https://doi.org/10.3390/jcm14175981

Vancouver

Ichim C, Boicean A, Todor SB, Anderco P, Bîrluțiu V. Fecal Microbiota Transplantation in Patients with Alcohol-Associated Cirrhosis: A Clinical Trial. Journal of Clinical Medicine. 2025;14(17):5981. doi:10.3390/jcm14175981

BibTeX
@article{Ichim2025,
  author = {Ichim, Cristian and Boicean, Adrian and Todor, Samuel Bogdan and Anderco, Paula and Bîrluțiu, Victoria},
  title = {Fecal Microbiota Transplantation in Patients with Alcohol-Associated Cirrhosis: A Clinical Trial},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {17},
  pages = {5981},
  doi = {10.3390/jcm14175981}
}
Kostenlos starten →